COGT Stock Up 38% after 5-Day Win Streak
Cogent Biosciences (COGT) stock hit day 5 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 38% return. The company has gained about $400 Mil in value over the last 5 days, with its current market capitalization at about $1.1 Bil. The stock remains 25.4% above its value at the end of 2024. This compares with year-to-date returns of 5.8% for the S&P 500.
Comparing COGT Stock Returns With The S&P 500
The following table summarizes the return for COGT stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | COGT | S&P 500 |
|---|---|---|
| 1D | 4.6% | -0.1% |
| 5D (Current Streak) | 37.7% | 0.8% |
| 1M (21D) | 73.4% | 4.3% |
| 3M (63D) | 83.5% | 15.4% |
| YTD 2025 | 25.4% | 5.8% |
| 2024 | 32.7% | 23.3% |
| 2023 | -49.1% | 24.2% |
| 2022 | 34.7% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 42 S&P constituents with 3 days or more of consecutive gains and 42 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 5 | 30 |
| 4D | 9 | 11 |
| 5D | 6 | 1 |
| 6D | 3 | 0 |
| 7D or more | 19 | 0 |
| Total >=3 D | 42 | 42 |
Key Financials for Cogent Biosciences (COGT)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $- | $- |
| Operating Income | $-208.1 Mil | $-275.9 Mil |
| Net Income | $-192.4 Mil | $-255.9 Mil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $- | $- |
| Operating Income | $-73.7 Mil | $-74.9 Mil |
| Net Income | $-67.9 Mil | $-72.0 Mil |
While COGT stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.